Status:
RECRUITING
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
Lead Sponsor:
Institut Curie
Conditions:
Metastatic Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible. Prese...
Detailed Description
A pre-screening consent will be obtained for NGS analysis on tumor tissue. Only patients with at least 1 mutation at NGS on the tumor tissue will ultimately be enrolled in the study, to have the possi...
Eligibility Criteria
Inclusion
- Histologically-proven NSCLC.
- Age ≥ 18 years.
- Advanced or metastatic stage IV.
- Treatment-naïve patient.
- Eligibility to first-line treatment with immune checkpoint inhibitor.
- Measurable disease according to RECIST 1.1 criteria on CT-Scan.
- Availability of expression of PD-L1 at immunohistochemistry analysis of the tumor biopsy.
- No ALK or EGFR gene alteration.
- Availability of tumor tissue for NGS analysis (7 slides).
- PS 0 or 1.
- Signed informed consent of the patient.
Exclusion
- No social security affiliation.
- Person under legal protection.
- Pregnant and breastfeeding women.
- Patients can participate to another clinical trial that is not modifying immunotherapy or immunotherapy/chemotherapy treatment nor study follow-up ; after investigator's information
Key Trial Info
Start Date :
May 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 3 2030
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04790682
Start Date
May 22 2021
End Date
June 3 2030
Last Update
September 18 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Ambroise Pare
Boulogne-Billancourt, France, 92100
2
Institut Curie
Paris, France, 75005
3
Institut Curie
Saint-Cloud, France, 92210